Anti-biotin immunoglobulin G1 antibody (Anti-biotin IgG1)

Anti-biotin IgG1 antibodies are monoclonal or polyclonal immunoglobulins that specifically recognize and bind to biotin (Vitamin B7) with high affinity. While not a traditional biological target involved in disease pathogenesis, they are significant in the fields of diagnostics and modular therapeutics. In clinical diagnostics, endogenous anti-biotin antibodies can cause significant interference in streptavidin-biotin-based immunoassays, leading to misinterpretation of critical biomarkers like troponin or thyroid-stimulating hormone (TSH) (PubMed: 31411144). In therapeutic development, anti-biotin IgG1 is utilized in "pre-targeting" strategies for cancer, where a biotinylated tumor-targeting antibody is administered first, followed by an anti-biotin antibody conjugated to a cytotoxic payload (Journal of Nuclear Medicine: 2006;47(12):1901-4). This approach aims to improve the therapeutic index by decoupling the slow-clearing targeting agent from the fast-clearing effector molecule. Furthermore, anti-biotin antibody fragments are being integrated into "universal" CAR-T cell platforms, allowing the T-cells to be redirected toward various antigens using biotinylated adapter molecules (Scientific Reports: 2016;6:24481).

Other names

Anti-biotin antibodyAnti-vitamin H antibodyAnti-biotin monoclonal antibodyAnti-biotin IgG

High-affinity binding and sequestration of biotin or biotinylated moieties to facilitate localization, detection, or clearance of specific molecules.